Abstract
The secosteroid hormone 1,25-dihydroxyvitamin D3 (1,25-(OH)2D3) is a key player in the regulation of bone mineralization and calcium homeostasis. In addition, 1,25-(OH)2D3 has antiproliferative and prodifferentiation effects on various cells in vitro and in vivo. The growthinhibitory properties of 1,25-(OH) 2D3 could be harnessed in the treatment of cancer. However, its use as an anti-cancer drug is limited because of the calcemic effects of pharmacological doses. In an attempt to dissociate the antiproliferative and calcemic effects, numerous vitamin D3 analogs were developed. The mechanisms by which 1,25-(OH)2D3 and 1,25-(OH)2D3 analogs exert their growth-inhibitory effects are not clear but include effects on cell differentiation, apoptosis, cell cycle regulation, metastases, and angiogenesis. In the current review aspects involved in the tumor suppressive activity of 1,25-(O H) 2D3 a nd 1,25-(O H) 2D3 a na logs will be a ddre sse d. The use of vita min D3 compounds, a lone or in combination with other drugs, in cancer treatment and the potential draw backs will also be discussed.
Current Drug Targets
Title: Vitamin D and Vitamin D Analogs in Cancer Treatment
Volume: 3 Issue: 1
Author(s): G.J.C.M. van den Bemd and G.T.G. Chang
Affiliation:
Abstract: The secosteroid hormone 1,25-dihydroxyvitamin D3 (1,25-(OH)2D3) is a key player in the regulation of bone mineralization and calcium homeostasis. In addition, 1,25-(OH)2D3 has antiproliferative and prodifferentiation effects on various cells in vitro and in vivo. The growthinhibitory properties of 1,25-(OH) 2D3 could be harnessed in the treatment of cancer. However, its use as an anti-cancer drug is limited because of the calcemic effects of pharmacological doses. In an attempt to dissociate the antiproliferative and calcemic effects, numerous vitamin D3 analogs were developed. The mechanisms by which 1,25-(OH)2D3 and 1,25-(OH)2D3 analogs exert their growth-inhibitory effects are not clear but include effects on cell differentiation, apoptosis, cell cycle regulation, metastases, and angiogenesis. In the current review aspects involved in the tumor suppressive activity of 1,25-(O H) 2D3 a nd 1,25-(O H) 2D3 a na logs will be a ddre sse d. The use of vita min D3 compounds, a lone or in combination with other drugs, in cancer treatment and the potential draw backs will also be discussed.
Export Options
About this article
Cite this article as:
G.J.C.M. van den Bemd and G.T.G. Chang , Vitamin D and Vitamin D Analogs in Cancer Treatment, Current Drug Targets 2002; 3 (1) . https://dx.doi.org/10.2174/1389450023348064
DOI https://dx.doi.org/10.2174/1389450023348064 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Toxic Epidermal Necrolysis and Antifolate Drugs in Cancer Chemotherapy
Current Drug Safety Cancer T Cell Immunotherapy with Bispecific Antibodies and Chimeric Antigen Receptors
Recent Patents on Anti-Cancer Drug Discovery The Role of Connexins in Carcinogenesis: Review of Current Knowledge
Current Signal Transduction Therapy The mTOR Signaling Network: Insights from Its Role During Embryonic Development
Current Medicinal Chemistry Castration-resistant Prostate Cancer: Novel Therapeutics Pre- or Post- Taxane Administration
Current Cancer Drug Targets The Chlorophyll Catabolite Pheophorbide a as a Photosensitizer for the Photodynamic Therapy
Current Medicinal Chemistry Therapeutic Transfer of DNA Encoding Adenoviral E1A
Recent Patents on Anti-Cancer Drug Discovery Inhibitor Binding to Hsp90: A Review of Thermodynamic, Kinetic, Enzymatic, and Cellular Assays
Current Protein & Peptide Science RUNX2 and Osteosarcoma
Anti-Cancer Agents in Medicinal Chemistry Preferentially Expressed Antigen in Melanoma (PRAME) and the PRAME Family of Leucine-Rich Repeat Proteins
Current Cancer Drug Targets The Promise of miRNA Replacement Therapy for Hepatocellular Carcinoma
Current Gene Therapy Extracellular Ca<sup>2+</sup> Selectively Enhances Adriamycin-induced Cell Death in Human Hepatoma Cells
Current Cancer Drug Targets Liquid Chromatographic Analysis of Methotrexate and Minocycline-relevance to the Determination in Plasma/Nanoparticulate Formulations
Current Chromatography Damage and Recovery of the Bone Marrow Microenvironment Induced by Cancer Chemotherapy – Potential Regulatory Role of Chemokine CXCL12/Receptor CXCR4 Signalling
Current Molecular Medicine Sirtuin Inhibitors: An Overview from Medicinal Chemistry Perspective
Anti-Cancer Agents in Medicinal Chemistry LncRNA, Important Player in Bone Development and Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets Stem Cell-based Tissue Engineering Approaches for Musculoskeletal Regeneration
Current Pharmaceutical Design Branched-Chain Amino Acids and Pigment Epithelium-Derived Factor: Novel Therapeutic Agents for Hepatitis C Virus-Associated Insulin Resistance
Current Medicinal Chemistry Drug-Related Cardiotoxicity for the Treatment of Haematological Malignancies in Elderly
Current Pharmaceutical Design Therapeutic Prospects for Parathyroid Hormone and Parathyroid Hormone Analogs
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents